Streetbeat News

Price Targets

PRAX

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Praxis Precision Medicine (NASDAQ:PRAX) and maintained a price target of $105. This endorsement from a reputable analyst could influence investor sentiment and potentially impact the stock's short-term performance.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 11:41 am

SASI

HC Wainwright & Co. analyst Scott Buck has downgraded Sigma Additive Solutions (NASDAQ:SASI) from Buy to Neutral and set a price target of $3.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 11:40 am

ASPI

HC Wainwright & Co. analyst Heiko Ihle has initiated coverage on ASP Isotopes (NASDAQ:ASPI) with a Buy rating and set a price target of $3.25.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 11:36 am

RIOT

HC Wainwright & Co. analyst Mike Colonnese has maintained a Buy rating on Riot Platforms (NASDAQ:RIOT) and increased the price target from $18 to $20.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 11:32 am

TVTX

HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Travere Therapeutics (NASDAQ:TVTX) and maintained an $18 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 11:28 am

ETNB

HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on 89bio (NASDAQ:ETNB) and maintained a $35 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 11:21 am

SDGR

Keybanc analyst Scott Schoenhaus has initiated coverage on Schrodinger (NASDAQ:SDGR) with an Overweight rating and set a price target of $38.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 11:12 am

ABSI

Keybanc analyst Scott Schoenhaus has initiated coverage on Absci (NASDAQ:ABSI), a biotech company, with an Overweight rating and a price target of $3. This new coverage could influence investor sentiment and potentially impact Absci's stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 11:09 am

XP

JP Morgan analyst Domingos Falavina upgraded XP Inc. (NASDAQ:XP) from Neutral to Overweight and increased the price target from $27 to $30.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 11:06 am

ABCL

Keybanc analyst Scott Schoenhaus has initiated coverage on AbCellera Biologics with an Overweight rating and set a price target of $6. The company is listed on NASDAQ under the ticker ABCL.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 11:03 am